Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15420/icr.2016:28:2 http://scihub22266oqcxt.onion/10.15420/icr.2016:28:2 C5808482!5808482!29588724     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Interv+Cardiol 2017 ; 12 (1): 13-7 Nephropedia Template TP {{tp|p=29588724|t=2017. PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent |pdf=|usr=}}{{29588724}} gab.com Text PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent JO: Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588724 #FOAvip Patients with diabetes have poor outcomes compared to the general patient population when undergoing percutaneous coronary intervention. The Cre8? (Alvimedica) drug-eluting stent (DES) has unique features that may improve clinical outcomes in patients with diabetes. These include abluminal reservoir technology, a proprietary polymer-free drug-release system consisting of reservoirs on the stent?s outer surface that control and direct drug release exclusively towards the vessel wall, and the Amphilimus? formulation, which enables enhanced drug tissue permeation, utilising fatty acid transport pathways. This is particularly advantageous in diabetic patients, since increased uptake of fatty acid occurs in diabetic cells. Furthermore, mTOR inhibitors (-limus drugs), which are utilised in DESs, are relatively ineffective in diabetic cells. Clinical efficacy and safety of the Cre8? in patients with diabetes has been demonstrated in a number of clinical trials and real-world studies, and further studies are on-going. Twit Text FOAVip PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent ????Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588724 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29588724 #FOAvip English Wikipedia <ref>{{Cite pmid|29588724}}</ref> PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent #MMPMID29588724 Byrne RA; Eeckhout E; Sardella G; Stella P; Verheye S Interv Cardiol 2017[May]; 12 (1): 13-7 PMID29588724show ga Patients with diabetes have poor outcomes compared to the general patient population when undergoing percutaneous coronary intervention. The Cre8? (Alvimedica) drug-eluting stent (DES) has unique features that may improve clinical outcomes in patients with diabetes. These include abluminal reservoir technology, a proprietary polymer-free drug-release system consisting of reservoirs on the stent?s outer surface that control and direct drug release exclusively towards the vessel wall, and the Amphilimus? formulation, which enables enhanced drug tissue permeation, utilising fatty acid transport pathways. This is particularly advantageous in diabetic patients, since increased uptake of fatty acid occurs in diabetic cells. Furthermore, mTOR inhibitors (-limus drugs), which are utilised in DESs, are relatively ineffective in diabetic cells. Clinical efficacy and safety of the Cre8? in patients with diabetes has been demonstrated in a number of clinical trials and real-world studies, and further studies are on-going. äPCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent (epmc).pdf DeepDyve Pubget Overpricing